Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment

References

• Remon J, Reguart N, Corral J, Lianes P. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev. 2015;41:27–34. doi:10.1016/j.ctrv.2014.10.007. PMID:25467107
   PubMed Web of Science ®Google Scholar
• Izzi V, Masuelli L, Tresoldi I, Foti C, Modesti A, Bei R. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer Lett. 2012;322:18–34. doi:10.1016/j.canlet.2012.02.034. PMID:22394996
   PubMed Web of Science ®Google Scholar
• Aerts JG, Lievense LA, Hoogsteden HC, Hegmans JP. Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res. 2014;3:34–45. doi:10.3978/j.issn.2218-6751.2013.11.04. PMID:25806279.
   PubMedGoogle Scholar
• Marcq E, Pauwels P, van Meerbeeck JP, Smits EL. Targeting immune checkpoints: New opportunity for mesothelioma treatment? Cancer Treat Rev. 2015;41:914–924. doi:10.1016/j.ctrv.2015.09.006. PMID:26433514
   PubMed Web of Science ®Google Scholar
• Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, Seepo S, Meyerson M, Pass HI. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75:264–269. doi:10.1158/0008-5472.CAN-14-1008. PMID:25488749
   PubMed Web of Science ®Google Scholar
• Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407–416. doi:10.1038/ng.3520. PMID:26928227
   PubMed Web of Science ®Google Scholar
• Stahel RA, Weder W, Felley-Bosco E, Petrausch U, Curioni-Fontecedro A, Schmitt-Opitz I, Peters S. Searching for targets for the systemic therapy of mesothelioma. Ann Oncol. 2015;26:1649–1660. doi:10.1093/annonc/mdv101. PMID:25722383
   PubMed Web of Science ®Google Scholar
• de Reyniès A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, Galateau-Sallé F, Copin MC, Hofman P, Cazes A, et al. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis.subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res. 2014;20:1323–1334. doi:10.1158/1078-0432.CCR-13-2429. PMID:24443521
   PubMed Web of Science ®Google Scholar
• Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung C, Hopf C, Savitski MM, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478:529–533. doi:10.1038/nature10509. PMID:21964340
   PubMed Web of Science ®Google Scholar
• Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, and Weinstock DM. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120:2843–2852. doi:10.1182/blood-2012-02-413021. PMID:22904298
   PubMed Web of Science ®Google Scholar
• Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3:308–323. doi:10.1158/2159-8290.CD-12-0418. PMID:23430699
   PubMed Web of Science ®Google Scholar
• Vázquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, Erba E, Ubezio P, Bello E, Libener R, et al. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts. Int J Cancer. 2017;140:197–207. doi:10.1002/ijc.30412. PMID:27594045
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404. doi:10.1158/2159-8290.CD-12-0095. PMID:22588877
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. doi:10.1126/scisignal.2004088. PMID:23550210
   PubMed Web of Science ®Google Scholar
• Gallagher SJ, Mijatov B, Gunatilake D, Gowrishankar K, Tiffen J, James W, Jin L, Pupo G, Cullinane C, McArthur GA, et al. Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. Pigment Cell Melanoma Res. 2014;27:1126–1137. doi:10.1111/pcmr.12282. PMID:24924589
   PubMed Web of Science ®Google Scholar
• Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, Beavis PA, Darcy PK, Martin BP, Spencer A, et al. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Rep. 2017;18:2162–74. doi:10.1016/j.celrep.2017.02.011. PMID:28249162
   PubMed Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3:e955691. doi:10.4161/21624011.2014.955691. PMID:25941621
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111. doi:10.1038/nri.2016.107. PMID:27748397
   PubMed Web of Science ®Google Scholar
• Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, Bosia A, Ghigo D, and Massaia M. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One. 2013;8:e60975. doi:10.1371/journal.pone.0060975. PMID:23593363
   PubMed Web of Science ®Google Scholar
• Salaroglio IC, Campia I, Kopecka J, Gazzano E, Orecchia S, Ghigo D, et al. Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. Oncotarget. 2015;6:1128–1142. doi:10.18632/oncotarget.2731. PMID:25544757
   PubMed Web of Science ®Google Scholar
• Vandermeers F, Neelature Sriramareddy S, Costa C, Hubaux R, Cosse JP, Willems L. The role of epigenetics in malignant pleural mesothelioma. Lung Cancer. 2013;81:311–318. doi:10.1016/j.lungcan.2013.05.014. PMID:23790315
   PubMed Web of Science ®Google Scholar
• Gallagher SJ, Tiffen JC, Hersey P. Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. Cancers (Basel). 2015;7:1959–1982. doi:10.3390/cancers7040870. PMID:26426052
   PubMed Web of Science ®Google Scholar
• McDonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ, Robinson BWS. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol. 2015;45:49–59. doi:10.1002/eji.201444722. PMID:25316312
   PubMed Web of Science ®Google Scholar
• Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J. 2006;27:1086–1095. doi:10.1183/09031936.06.00135305. PMID:16540497
   PubMed Web of Science ®Google Scholar
• Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer. 2010;10:e464. doi:10.1186/1471-2407-10-464. PMID:20804550
   PubMed Web of Science ®Google Scholar
• Ujiie H, Kadota K, Nitadori JI, Aerts JG, Woo KM, Sima CS, Travis WD, Jones DR, Krug LM, and Adusumilli PS. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers. Oncoimmunology. 2015;4:e1009285. doi:10.1080/2162402X.2015.1009285. PMID:26155428
   PubMed Web of Science ®Google Scholar
• Miselis NR, Lau BW, Wu Z, Kane AB. Kinetics of host cell recruitment during dissemination of diffuse malignant peritoneal mesothelioma. Cancer Microenviron. 2010;4:39–50. doi:10.1007/s12307-010-0048-1. PMID:21505561
   PubMedGoogle Scholar
• Yu Z, Tan Z, Lee BK, Tang J, Wu X, Cheung KW, Lo NTL, Man K, Liu L, Chen Z. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells. Oncotarget. 2015;6:32426–32438. doi:10.18632/oncotarget.5856. PMID:26431275
   PubMed Web of Science ®Google Scholar
• Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, et al. Malignant Mesothelioma Effusions Are Infiltrated by CD3(+) T Cells Highly Expressing PD-L1 and the PD-L1(+) Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. J Thorac Oncol. 2016;11:1993–2005. doi:10.1016/j.jtho.2016.07.033. PMID:27544053
   PubMed Web of Science ®Google Scholar
• Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One. 2015;10:e0121071. doi:10.1371/journal.pone.0121071. PMID:25774992
   PubMed Web of Science ®Google Scholar
• Awad MM, Jones RE, Liu H, Lizotte PH, Ivanova EV, Kulkarni M, Herter-Sprie GS, Liao X, Santos AA, Bittinger MA, et al. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. Cancer Immunol Res. 2016;4:1038–1048. doi:10.1158/2326-6066.CIR-16-0171. PMID:27856426
   PubMed Web of Science ®Google Scholar
• Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, Yokoyama Y, Kossenkov AV, Bradner JE, Conejo-Garcia JR, et al. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Rep. 2016;16:2829–2837. doi:10.1016/j.celrep.2016.08.032. PMID:27626654
   PubMed Web of Science ®Google Scholar
• Lievense LA, Bezemer K, Cornelissen R, Kaijen-Lambers ME, Hegmans JP, Aerts JG. Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients. Lung Cancer. 2017;107:36–40. doi:10.1016/j.lungcan.2016.04.015. PMID:27168021
   PubMed Web of Science ®Google Scholar
• Adeegbe D, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, Dries R, Li Y, Liu S, Wang X, et al. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-small Cell Lung Cancer. Cancer Discov. 2017;7:852–867. doi:10.1158/2159-8290.CD-16-1020. PMID:28408401
   PubMed Web of Science ®Google Scholar
• Hamaidia M, Staumont B, Duysinx B, Louis R, Willems L. Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators. Curr Top Med Chem. 2016;16:777–787. doi:10.2174/1568026615666150825141152. PMID:26303419
   PubMed Web of Science ®Google Scholar
• Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016;3:196–204. doi:10.1016/S2352-3026(16)00021-1. PMID:27063978
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61. doi:10.1038/nm1523. PMID:17187072
   PubMed Web of Science ®Google Scholar